Sponsor: IlluminaIn this Clinical OMICs webinar, sponsored by Illumina, we will discover how combining molecular and immune profiling's power to drive molecular-based testing is improving stratification methods and patient outcomes. Additionally, our expert panelist will showcase the impact of a scalable, comprehensive assay, and infrastructure in the context of drug development.
Sponsor: UltivueIn this Keynote Webinar, sponsored by Illumina, two leading researchers will show how genomic technologies are tackling the COVID-19 pandemic—Alex Greninger, MD, PhD, (University of Washington School of Medicine) and Darrell Dinwiddie PhD, (University of New Mexico Health Sciences Center).
Sponsor: QiagenIn this webinar, we will describe Quest’s LeukoVantage assay, an NGS test designed specifically for detecting clinically relevant variants in myeloid malignancies, and its partnership with N-of-One, a QIAGEN company, for expert interpretation.
Sponsor: IlluminaIn this inaugural Clinical OMICs Keynote webinar, we are proud to host two renowned leaders in the field of genomic medicine, Drs Stephen Kingsmore and Robert Green, who will discuss their pioneering work in the field of newborn genome sequencing and analysis.
Sponsor: IlluminaIn this Clinical OMICs KEYNOTE webinar, sponsored by Illumina, we are delighted to host two true pioneers of clinical genome sequencing, bioinformatician Dr. Liz Worthey and geneticist Dr. Howard Jacob, who will reflect on a decade of progress in clinical genome analysis and discuss the future challenges confronting the field.
Sponsor: OwkinIn this Clinical OMICs webinar, sponsored by Owkin, a distinguished panel of breast cancer experts and machine learning researchers, including world-renowned expert Dr. Fabrice André, will explore how clinicians and data scientists can collaborate to accelerate research through the application of novel computational and federated learning techniques.
Sponsor: Bio-RadIn this Clinical OMICs webinar, sponsored by Bio-Rad, IncellDx presents an overview of CCR5 antagonists and the ddPCR data that enabled validation of their hypothesis to move 4 CCR5 inhibitors into trials for treatment of COVID-19.
Sponsor: UltivueIn this exciting new webinar, sponsored by Ultivue, we will explore the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials.
Sponsor: ThermoFisher Scientific
Broadcast Date: October 1, 2019
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Accurate monitoring of cell signaling pathway proteins, particularly tyrosine phosphorylation (pTyr)...